Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Small Cell Lung Carcinoma × Doxorubicin × Clear all

Phase

Phase 1 4 Phase 3 1 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 62 Lymphoma 50 Lymphoma, Large B-Cell, Diffuse 38 Precursor Cell Lymphoblastic Leukemia-Lymphoma 27 Hodgkin Disease 25 Lymphoma, Follicular 24 Sarcoma 23 Lymphoma, Non-Hodgkin 22 Leukemia 18 Burkitt Lymphoma 17 Endometrial Neoplasms 15 Neuroblastoma 13 Multiple Myeloma 13 Ovarian Neoplasms 12 Carcinoma, Hepatocellular 12 Lymphoma, Large-Cell, Immunoblastic 11 Lymphoma, Mantle-Cell 8 Liposarcoma 8 Leiomyosarcoma 8 Histiocytoma, Malignant Fibrous 8 Urinary Bladder Neoplasms 7 Neoplasms 7 Lymphoma, Large-Cell, Anaplastic 7 Sarcoma, Synovial 6 Neurofibrosarcoma 6 Lymphoma, B-Cell, Marginal Zone 6 Hemangiosarcoma 6 HIV Infections 6 Fibrosarcoma 6 Acquired Immunodeficiency Syndrome 6

Interventions

Etoposide 30 Carboplatin 28 Cisplatin 20 Topotecan 19 atezolizumab 9 durvalumab 7 PM 01183 6 Irinotecan 5 amrubicin 4 AMG 757 4 rovalpituzumab tesirine 3 PE regimen 3 Dexamethasone 3 tremelimumab 2 pembrolizumab 2 etoposide phosphate 2 apatinib 2 Vitamin E 2 Tiragolumab 2 RRx-001 2 Magnetic Resonance Spectroscopy 2 trilaciclib 1 toripalimab 1 tislelizumab 1 racotumomab 1 olaparib 1 obatoclax 1 marimastat 1 isophosphamide mustard 1 irinotecan sucrosofate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02566993 2021-10-28

ATLANTIS

PharmaMar

Phase 3 Completed

613 enrolled 46 charts

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡